Peng Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peng Cheng has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Hao Hu
Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital Affiliated to Navy Medical University, Shanghai, China
2 shared publications- Baohua Qian
Department of Transfusion Medicine, Changhai Hospital, Naval Medical University, Shanghai, China
1 shared publication - Bo Li
Department of Hepatobiliary Pancreatic Surgery
1 shared publication Chao Wang
The Second Military Medical University, Shanghai 200433, P.R. China
1 shared publicationChen-Ming Ni
Department of Pancreatic Hepatobiliary Surgery, Changhai Hospital, Shanghai 200433, P.R. China
1 shared publicationChenming Ni
Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital Affiliated to Navy Medical University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 3 December 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (2)
Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients
T cells targeting a KRAS mutation can induce durable tumor regression in some patients with metastatic epithelial cancer. It is unknown whether T cells targeting mutant KRAS that are capable of killing tumor cells can be identified from peripheral blood of patients with pancreatic cancer. We developed an in vitro stimulation approach and identified HLA-A*11:01–restricted KRAS G12V–reactive CD8 + T cells and HLA-DRB1*15:01–restricted KRAS G12V–reactive CD4 + T cells from peripheral blood of 2 out of 6 HLA-A*11:01–positive patients with pancreatic cancer whose tumors expressed KRAS G12V. The HLA-A*11:01–restricted KRAS G12V–reactive T cell receptor (TCR) was isolated and validated to specifically recognize the KRAS G12V 8–16 neoepitope. While T cells engineered to express this TCR specifically recognized all 5 tested human HLA-A*11:01 + and KRAS G12V + pancreatic cancer organoids, the recognition was often modest, and tumor cell killing was observed in only 2 out of 5 organoids. IFN-γ priming of the organoids enhanced the recognition and killing by the TCR-engineered T cells. The TCR-engineered T cells could significantly slow the growth of an established organoid-derived xenograft in immunodeficient mice. Our data suggest that this TCR has potential for use in TCR-gene therapy, but additional strategies that enhance tumor recognition by the TCR-engineered T cells likely will be required to increase clinical activity.
- 3 December 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (2)
Open AccessIdentification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients
T cells targeting a KRAS mutation can induce durable tumor regression in some patients with metastatic epithelial cancer. It is unknown whether T cells targeting mutant KRAS that are capable of killing tumor cells can be identified from peripheral blood of patients with pancreatic cancer. We developed an in vitro stimulation approach and identified HLA-A*11:01–restricted KRAS G12V–reactive CD8 + T cells and HLA-DRB1*15:01–restricted KRAS G12V–reactive CD4 + T cells from peripheral blood of 2 out of 6 HLA-A*11:01–positive patients with pancreatic cancer whose tumors expressed KRAS G12V. The HLA-A*11:01–restricted KRAS G12V–reactive T cell receptor (TCR) was isolated and validated to specifically recognize the KRAS G12V 8–16 neoepitope. While T cells engineered to express this TCR specifically recognized all 5 tested human HLA-A*11:01 + and KRAS G12V + pancreatic cancer organoids, the recognition was often modest, and tumor cell killing was observed in only 2 out of 5 organoids. IFN-γ priming of the organoids enhanced the recognition and killing by the TCR-engineered T cells. The TCR-engineered T cells could significantly slow the growth of an established organoid-derived xenograft in immunodeficient mice. Our data suggest that this TCR has potential for use in TCR-gene therapy, but additional strategies that enhance tumor recognition by the TCR-engineered T cells likely will be required to increase clinical activity.
- Open Access
- 1 December 2019
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 18, 155-165
Menin Coordinates C/EBPβ-Mediated TGF-β Signaling for Epithelial-Mesenchymal Transition and Growth Inhibition in Pancreatic Cancer
- 1 December 2019
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 18, 155-165
Open AccessMenin Coordinates C/EBPβ-Mediated TGF-β Signaling for Epithelial-Mesenchymal Transition and Growth Inhibition in Pancreatic Cancer